Top

11-06-2015 | Gastric cancer | Book chapter | Article

2. Epidemiology of Gastric Cancer

Authors: Massimo Rugge, MD, FAC, G, Matteo Fassan, MD, PhD, David Y. Graham, MD

Publisher: Springer International Publishing

Abstract

Gastric cancer is the third leading cause of cancer-related death worldwide. Despite a decrease in its incidence in some regions of the world, gastric cancer still poses a major clinical challenge because most cases are diagnosed in an advanced stage, with a poor prognosis and limited treatment options. The most common causes are Helicobacter pylori infection (proven), Epstein-Barr virus infection (suspected), and familial. Major predisposing factors include high salt intake, smoking, and a familial genetic component. Primary prevention (i.e., H. pylori eradication) is increasingly recommended. Despite a growing understanding of both the phenotypic alterations and the molecular mechanisms occurring during gastric cancer carcinogenesis, no reliable biomarkers are available as yet for use in gastric cancer secondary prevention strategies.

Parkin DM. The global health burden of infectionassociated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.PubMedCrossRef

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMedCrossRef

Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther. 2014;14:947–54.PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107:230–6.PubMedCrossRef

Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol. 2013;24:693–701.PubMedCrossRef

Yamamoto H, Watanabe Y, Maehata T, Morita R, Yoshida Y, et al. An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. World J Gastroenterol. 2014;20:3927–37.PubMedCentralPubMedCrossRef

Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42:211–7.PubMedCentralPubMedCrossRef

Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. 417 p.

10.

Santoro E. The history of gastric cancer: legends and chronicles. Gastric Cancer. 2005;8:71–4.PubMedCrossRef

11.

Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol. 2010;45:1–8.PubMedCentralPubMedCrossRef

12.

Gray H, Balfour D. Cancer of the stomach. Am J Cancer. 1934;22:249–86.

13.

Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20:5191–204.PubMedCentralPubMedCrossRef

14.

Faber K. Chronic gastritis: its relation to achylia and ulcer. Lancet. 1927;2:902–7.

15.

Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med. 1951;34:1331–1348.PubMedCrossRef

16.

Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60.PubMedCrossRef

17.

Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–5.

18.

Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.PubMedCrossRef

19.

Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43(Suppl 4):S373–84.PubMedCrossRef

20.

Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed

21.

Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.PubMed

22.

Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef

23.

The Cancer Genome Atlas Research N, Analysis Working Group: Dana-Farber Cancer I, Institute for Systems B, University of Southern C, Memorial Sloan Kettering Cancer C, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef

24.

Wang K, Yuen ST, Xu J, Lee SP, Yan HH, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573–82.PubMedCrossRef

25.

Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7.PubMedCrossRef

26.

Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344:1904–9.PubMedCrossRef

27.

Pizzi M, Saraggi D, Fassan M, Megraud F, Di Mario F, et al. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis. Dig Dis. 2014;32:265–74.PubMedCrossRef

28.

Rugge M, Fassan M, Graham DY. Clinical guidelines: secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol. 2012;9:128–9.PubMedCrossRef

29.

Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics. 2013;14:589.PubMedCentralPubMedCrossRef

30.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. Geneva: The Agency: Secretariat of the World Health Organization Distributor; 1994. 270 p.

31.

Helicobacter, Cancer Collaborative G. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347–53.CrossRef

32.

Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–73.PubMedCentralPubMedCrossRef

33.

Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol. 2013;23:492–501.PubMedCrossRef

34.

Delahay RM, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2012;17(Suppl 1):9–15.PubMedCrossRef

35.

Holcombe C. Helicobacter pylori: the African enigma. Gut. 1992;33:429–31.PubMedCentralPubMedCrossRef

36.

Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 2008;99:195–201.PubMedCrossRef

37.

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137:824–33.PubMedCentralPubMedCrossRef

38.

Tsugane S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci. 2005;96:1–6.PubMedCrossRef

39.

Jakszyn P, Gonzalez CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol. 2006;12:4296–303.PubMedCentralPubMed

40.

Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130:745–53.PubMedCrossRef

41.

Gonzalez CA, Pera G, Agudo A, Palli D, Krogh V, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2003;107:629–34.PubMedCrossRef

42.

Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Alcohol consumption, smoking and risk of gastric cancer: case-control study from Moscow, Russia. Cancer Causes Control. 2000;11:363–71.PubMedCrossRef

43.

Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol. 2012;23:28–36.PubMedCrossRef

44.

Noto JM, Gaddy JA, Lee JY, Piazuelo MB, Friedman DB, et al. Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest. 2013;123:479–92.PubMedCentralPubMedCrossRef

45.

Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2006;15:1998–2001.PubMedCrossRef

46.

Plummer M, Vivas J, Lopez G, Bravo JC, Peraza S, et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst. 2007;99:137–46.PubMedCrossRef

47.

You WC, Blot WJ, Chang YS, Ershow AG, Yang ZT, et al. Diet and high risk of stomach cancer in Shandong, China. Cancer Res. 1988;48:3518–23.PubMed

48.

You WC, Brown LM, Zhang L, Li JY, Jin ML, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–83.PubMedCrossRef

49.

Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21–33.PubMedCrossRef

50.

Fassan M, Baffa R, Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol. 2013;27:159–69.PubMedCrossRef

51.

Tsukanov VV, Butorin NN, Maady AS, Shtygasheva OV, Amelchugova OS, et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia. Helicobacter. 2011;16:107–12.PubMedCrossRef

52.

Naess O, Strand BH, Smith GD. Childhood and adulthood socioeconomic position across 20 causes of death: a prospective cohort study of 800,000 Norwegian men and women. J Epidemiol Community Health. 2007;61:1004–9.PubMedCentralPubMedCrossRef

53.

Nagel G, Linseisen J, Boshuizen HC, Pera G, Del Giudice G, et al. Socioeconomic position and the risk of gastric and oesophageal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Epidemiol. 2007;36:66–76.PubMedCrossRef

54.

Shimizu H, Mack TM, Ross RK, Henderson BE. Cancer of the gastrointestinal tract among Japanese and White immigrants in Los Angeles County. J Natl Cancer Inst. 1987;78:223–8.PubMed

55.

Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control. 2007;14:78–85.PubMed

56.

Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303:1723–8.PubMedCentralPubMedCrossRef

57.

Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–56.PubMedCrossRef

58.

Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23:3–9.PubMedCentralPubMedCrossRef

59.

Rugge M, Fassan M, Cavallin F, Zaninotto G. Re: risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2012;104:1771–2.PubMedCrossRef

60.

Rugge M, Zaninotto G, Parente P, Zanatta L, Cavallin F, et al. Barrett’s esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg. 2012;256:788–94; discussion 794–785.PubMedCrossRef

61.

Bornschein J, Leja M, Kupcinskas J, Link A, Weaver J, et al. Molecular diagnostics in gastric cancer. Front Biosci (Landmark Ed). 2014;19:312–38.CrossRef

62.

Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74–94.PubMedCentralPubMedCrossRef

63.

Bornschein J, Kandulski A, Selgrad M, Malfertheiner P. From gastric inflammation to gastric cancer. Dig Dis. 2010;28:609–14.PubMedCrossRef

64.

Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol. 2011;17:5231–9.PubMedCentralPubMedCrossRef

65.

Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, et al. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer. 2014;17:442–9.PubMedCrossRef

66.

Wang K, Kan J, Yuen ST, Shi ST, Chu KM, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43:1219–23.PubMedCrossRef

67.

Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44:570–4.PubMedCrossRef

68.

Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res. 2009;69:8223–30.PubMedCentralPubMedCrossRef

69.

Dong B, Xie YQ, Chen K, Wang T, Tang W, et al. Differences in biological features of gastric dysplasia, indefinite dysplasia, reactive hyperplasia and discriminant analysis of these lesions. World J Gastroenterol. 2005;11:3595–600.PubMedCentralPubMedCrossRef

70.

Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, et al. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4:279–94.PubMedCrossRef

71.

Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, et al. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol. 2009;40:1534–42.PubMedCrossRef

72.

Lu XX, Yu JL, Ying LS, Han J, Wang S, et al. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer. 2012;118:5507–17.PubMedCrossRef

73.

Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int. 2010;60:337–50.PubMedCrossRef

74.

Compare D, Rocco A, Liguori E, D’Armiento FP, Persico G, et al. Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol. 2011;64:677–82.PubMedCrossRef

75.

Zheng Z, Andersson AF, Ye W, Nyren O, Normark S, et al. A method for metagenomics of Helicobacter pylori from archived formalin-fixed gastric biopsies permitting longitudinal studies of carcinogenic risk. PLoS ONE. 2011;6:e26442.PubMedCentralPubMedCrossRef

76.

Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–46.PubMedCentralPubMedCrossRef

77.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.PubMedCentralPubMedCrossRef

78.

Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205–23.PubMedCrossRef

79.

Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol. 2000;24:167–76.PubMedCrossRef

80.

Correa P, Piazuelo MB. Natural history of Helicobacter pylori infection. Dig Liver Dis. 2008;40:490–6.PubMedCentralPubMedCrossRef

81.

Fassan M, Pizzi M, Farinati F, Nitti D, Zagonel V, et al. Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. Am J Clin Pathol. 2012;137:727–32.PubMedCrossRef

82.

Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–81.PubMedCrossRef

83.

Price AB. The Sydney system: histological division. J Gastroenterol Hepatol. 1991;6:209–22.PubMedCrossRef

84.

Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36:228–33.PubMedCrossRef

85.

Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150–8.PubMedCrossRef

86.

Rugge M, Genta RM, Group O. Staging gastritis: an international proposal. Gastroenterology. 2005;129:1807–8.PubMedCrossRef

87.

Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010;31:1104–11.PubMed

88.

Daugule I, Sudraba A, Chiu HM, Funka K, Ivanauskas A, et al. Gastric plasma biomarkers and operative link for gastritis assessment gastritis stage. Eur J Gastroenterol Hepatol. 2011;23:302–7.PubMedCrossRef

89.

Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo GC, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011;17:4596–601.PubMedCentralPubMedCrossRef

90.

den Hoed CM, Holster IL, Capelle LG, de Vries AC, den Hartog B, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy. 2013;45:249–56.PubMedCrossRef

91.

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–64.PubMedCrossRef

Medicine Matters Oncology

Abstract